Literature DB >> 15110795

Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation?

Ben Wielockx1, Claude Libert, Carole Wilson.   

Abstract

Matrilysin or MMP-7, one of the smallest of all known matrix metalloproteinases (MMPs), has been studied extensively in many different tumor types, since its discovery more than 20 years ago. However, research during the past several years has revealed that this protease also plays an essential role in innate immunity, and, more particularly, in inflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15110795     DOI: 10.1016/j.cytogfr.2003.12.001

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  23 in total

Review 1.  Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility.

Authors:  György Dormán; Sándor Cseh; István Hajdú; László Barna; Dénes Kónya; Krisztina Kupai; László Kovács; Péter Ferdinandy
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

2.  Diabetes Associated Markers After Bariatric Surgery: Fetuin-A, but Not Matrix Metalloproteinase-7, Is Reduced.

Authors:  Po-Jen Yang; Kong-Han Ser; Ming-Tsan Lin; Hsiao-Ching Nien; Chiung-Nien Chen; Wei-Shiung Yang; Wei-Jei Lee
Journal:  Obes Surg       Date:  2015-12       Impact factor: 4.129

3.  Relationship of Helicobacter pylori to Bcl-2 family expression, DNA content, and pathological characteristics of gastric cancer.

Authors:  Mohamed El-Shahat; Samir El-Masry; Mahmoud Lotfy; Ayman El-Meghawry El-Kenawy; Wesam A Nasif
Journal:  Int J Gastrointest Cancer       Date:  2005

Review 4.  Ovarian cancer: involvement of the matrix metalloproteinases.

Authors:  Linah Al-Alem; Thomas E Curry
Journal:  Reproduction       Date:  2015-04-27       Impact factor: 3.906

5.  Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs).

Authors:  D Dirk Bonnema; Carson S Webb; Weems R Pennington; Robert E Stroud; Amy E Leonardi; Leslie L Clark; Catherine D McClure; Laura Finklea; Francis G Spinale; Michael R Zile
Journal:  J Card Fail       Date:  2007-09       Impact factor: 5.712

6.  Matrilysin inhibits proliferation and modulates sensitivity of lung cancer cells to FasL-mediated apoptosis.

Authors:  Hui Liu; Jing Huang; Benquan Wu; Yuqi Zhou; Jiaxin Zhu; Tiantuo Zhang
Journal:  Med Oncol       Date:  2008-03-14       Impact factor: 3.064

7.  Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background.

Authors:  Michelle D Martin; Kathy J Carter; Sharon R Jean-Philippe; Mayland Chang; Shahriar Mobashery; Sophie Thiolloy; Conor C Lynch; Lynn M Matrisian; Barbara Fingleton
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

8.  Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice.

Authors:  Elihu Aranday Cortes; Daryan Kaveh; Javier Nunez-Garcia; Philip J Hogarth; H Martin Vordermeier
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

9.  Chronic exposure to exogenous matrilysin induces chemoresistance and enhances Bcl-2 expression in A549 lung adenocarcinoma cells.

Authors:  Hui Liu; Tiantuo Zhang; Benquan Wu; Jing Huang; Yuqi Zhou; Jiaxin Zhu
Journal:  Mol Biol Rep       Date:  2008-12-24       Impact factor: 2.316

10.  Syndecan-2 functions as a docking receptor for pro-matrix metalloproteinase-7 in human colon cancer cells.

Authors:  Heui-Young Ryu; Jiseon Lee; Sanghwa Yang; Haein Park; Sojoong Choi; Kyeong-Cheon Jung; Seung-Taek Lee; Je-Kyung Seong; Inn-Oc Han; Eok-Soo Oh
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.